ArticleOncology letters2026
NDC80 kinetochore complex component is a potential molecular target of adenoid cystic carcinoma.
Article in Oncology letters, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Adenoid cystic carcinoma (ACC) is a slow-growing malignant tumour that primarily originates from the major and minor salivary glands. The relationship between the NDC80 kinetochore complex component (NUF2) and ACC remains to be elucidated. The present study obtained gene expression information from the Gene Expression Omnibus database (GSE88804 and GSE153002). Differentially expressed genes were identified by using the 'limma' package in R. A protein-protein interaction network was constructed with the Search Tool for Retrieval of Interacting Genes/Proteins database and key genes were extracted using Cytoscape software. Analysis of differential expression levels of hub genes in tumour and normal tissue was performed using Tumour Immune Estimation Resource (TIMER) and GSE36820 profiles. Gene Ontology enrichment was subsequently analysed based on differences in NUF2 expression in tumour tissues. In addition, single sample Gene Set Enrichment Analysis (ssGSEA) was used for the quantitative analysis of immune cell infiltration in ACC. Western blotting and immunohistochemistry were used to assess NUF2 expression levels in tumour and adjacent non-tumour tissues. Small interfering RNA (siRNA) was used to decrease NUF2 expression in ACC cell lines. The biological functions of NUF2 were analysed using Cell Counting Kit-8 and wound healing assays. A total of 248 differential genes were identified by differential expression analyses, with 113 genes upregulated and 135 downregulated. A total of 7 hub genes, namely, CDK1, budding uninhibited by benzimidazoles 1 mitotic checkpoint serine/threonine kinase B, DNA topoisomerase II α, cyclin B2, NUF2, budding uninhibited by benzimidazoles 1 and centromere protein F, were obtained using the 'cytoHubba' plugin. The TIMER, standardized and GSE36820 databases revealed that the expression levels of NUF2 were higher in ACC tissues compared with normal tissue samples. Western blotting and immunohistochemical staining of ACC tissues provided evidence of NUF2 upregulation in ACC tissue compared with normal tissue. NUF2-related genes were enriched in 'ameboidal-type cell migration', 'collagen-containing extracellular matrix' and 'actin binding'. ssGSEA analysis revealed that the expression level of NUF2 was notably associated with activated CD4
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.